JNJ vs PLTR: Johnson & Johnson and Palantir Technologies compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- Johnson & Johnson is the larger company, worth $632.9B, about 1.3 times Palantir Technologies.
- Palantir Technologies grew revenue faster over the last year (+92.8% vs +6.6%).
- On earnings, Johnson & Johnson is the cheaper stock (30.5x vs 226.9x).
- Palantir Technologies's price assumes faster free cash flow growth: about 38% a year, against 11% for Johnson & Johnson (reverse DCF).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | JNJ | PLTR |
|---|---|---|
| Market cap | $632.9B | $484.0B |
| Share price | $261.44 | $194.12 |
| Revenue (last fiscal year) | $94.2B | $4.5B |
| Free cash flow (last fiscal year) | $19.7B | $2.1B |
| Revenue growth, last year | +6.6% | +92.8% |
| Revenue growth per year, last 5 fiscal years | +4.6% | +30.5% |
| Operating margin | — | 42.8% |
| Net margin | 21.5% | 49.0% |
| Return on equity | 24.8% | 30.9% |
| P/E (trailing) | 30.5x | 226.9x |
| Price / free cash flow | 32.1x | 230.4x |
| EV / EBITDA | 19.4x | 153.6x |
| FCF growth the price implies | 11.2% | 38.2% |
| Dividend yield | 2.0% | — |
| Debt / equity | 1.37x | 0.18x |
| Fundamental grade | C | B |
| Superinvestors holding it | 17 | 7 |
| Insider purchases, last 12 months | 10 | 10 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
Johnson & Johnson
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $78.7B | $19.8B | — |
| 2022 | $80.0B | $17.2B | — |
| 2023 | $85.2B | $18.2B | — |
| 2024 | $88.8B | $19.8B | — |
| 2025 | $94.2B | $19.7B | — |
Palantir Technologies
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $1.5B | $321M | -26.7% |
| 2022 | $1.9B | $184M | -8.5% |
| 2023 | $2.2B | $697M | 5.4% |
| 2024 | $2.9B | $1.1B | 10.8% |
| 2025 | $4.5B | $2.1B | 31.6% |
Where the revenue comes from
Johnson & Johnson · by segments, 2025
Innovative Medicine$60.4B64%
MedTech$33.8B36%
Palantir Technologies · by segments, 2025
Government Operating Segment$2.4B54%
Commercial$2.1B46%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open JNJ in InvestinglyQuestions
Which is bigger, Johnson & Johnson or Palantir Technologies?
Johnson & Johnson (JNJ), at $632.9B against $484.0B.
Is JNJ or PLTR cheaper?
By trailing P/E, Johnson & Johnson (30.5x) is cheaper than Palantir Technologies (226.9x). A lower multiple can also mean the market expects less growth.
Which grows faster, JNJ or PLTR?
Palantir Technologies: revenue grew +92.8% over the last year, against +6.6%.
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.